Colorectal Cancer

**Major finding:** Vitamin C inhibits GAPDH, causing selective killing of KRAS- and BRAF-mutant colorectal cancer cells.

**Mechanism:** GLUT1-mediated uptake of DHA leads to glutathione depletion, ROS accumulation, and GAPDH inactivation.

**Impact:** High-dose vitamin C is a potential treatment for KRAS- and BRAF-mutant colorectal cancer.

---

**VITAMIN C TARGETS GAPDH TO KILL KRAS- AND BRAF-MUTANT CANCER CELLS**

About half of colorectal cancers harbor activating mutations in either KRAS or BRAF. KRAS- and BRAF-mutant tumors exhibit increased glucose uptake and expression of the glucose transporter GLUT1 also known as SLC2A1, suggesting that exploiting the reliance of these tumors on glycolysis may represent a possible therapeutic strategy. GLUT1 also transports dehydroascorbate (DHA), the oxidized form of vitamin C, into the cell, where it is reduced to vitamin C in a process that consumes the antioxidant glutathione (GSH). To test the hypothesis that increased DHA uptake would disrupt redox homeostasis and kill KRAS- or BRAF-mutant cells, Yun and colleagues treated a panel of colorectal cancer cell lines with vitamin C. Although both wild-type and mutant colorectal cancer cells preferentially took up DHA over vitamin C via the GLUT1 receptor, the increased GLUT1 expression in KRAS- and BRAF-mutant cells resulted in enhanced vitamin C uptake compared with wild-type cells. Vitamin C treatment was selectively cytotoxic in KRAS- and BRAF-mutant cells in vitro, and reduced tumor growth in vivo in xenografts and the ApcMinG12D transgenic model of intestinal cancer. In contrast, whereas GLUT1 overexpression was sufficient to increase vitamin C uptake in wild-type cells, it did not render them sensitive to the cytotoxic effects, suggesting that oncogene-induced metabolic reprogramming is required for vitamin C-mediated toxicity. Mechanistically, DHA uptake and reduction to vitamin C depleted cellular GSH levels, resulting in increased reactive oxygen species (ROS) in KRAS- and BRAF-mutant cells. Furthermore, vitamin C induced ROS-dependent inactivation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) via posttranslational modifications and depletion of NAD+ substrate, leading to inhibition of glycolysis, decreased ATP levels, and cell death. Taken together, these results provide a mechanism for the selective killing of KRAS- and BRAF-mutant cancer cells by vitamin C and support continued investigation of vitamin C in human tumors.


---

**Epigenetics**

**Major finding:** Tumors with SWI/SNF subunit mutations depend on both catalytic and noncatalytic activity of EZH2.

**Concept:** EZH2 dependence is a shared feature of cancer cells harboring inactivating mutations in SWI/SNF subunits.

**Impact:** EZH2 enzymatic inhibitors may not be sufficient to disrupt the oncogenic effects of EZH2.

---

**NONCATALYTIC EZH2 ACTIVITY IS REQUIRED IN SWI/SNF-MUTANT CANCERS**

Components of the SWI/SNF chromatin remodeling complex are mutated in approximately 20% of human cancers. An antagonistic relationship has been reported between the SWI/SNF subunit SMARCB1 (also known as Snf5) and EZH2, the catalytic methyltransferase subunit of polycomb repressive complex 2 (PRC2), wherein SMARCB1-deficient tumors are genetically dependent on unrestrained EZH2 function. Kim and colleagues found that most cancer cell lines with inactivating mutations in genes encoding other SWI/SNF subunits frequently mutated in cancer, such as ARID1A, SMARCA4 (BRG1), and PBRM1, were also dependent on EZH2 and selectively sensitive to EZH2 depletion. The SWI/SNF-mutant cell lines that did not require EZH2 were enriched for activating RAS pathway mutations, suggesting that RAS mutations reduce the dependence of SWI/SNF-mutant tumors on EZH2. Inhibitors targeting EZH2 histone methyltransferase activity were in clinical trials; however, it is unclear if EZH2 catalytic activity is required for the oncogenic effects of EZH2 in SWI/SNF-mutant cancers. GSK126, an enzymatic inhibitor of EZH2 histone methyltransferase activity, reduced H3K27 trimethylation in all cells, but although all SWI/SNF-mutant cells were sensitive to EZH2 knockdown in vitro and in vivo, only some were sensitive to GSK126. Surprisingly, EZH2 mutants lacking methyltransferase activity were largely able to rescue the effects of EZH2 knockdown, suggesting that the effects of EZH2 depletion on SWI/SNF-mutant cells are not entirely due to loss of EZH2 enzymatic activity. SAH-EZH2, a stapled peptide that blocks H3K27 trimethylation by destabilizing the PRC2 complex and inducing EZH2 degradation, inhibited the growth of SWI/SNF-mutant cancer cells, including those that were insensitive to GSK126. Together, these data suggest that a methyltransferase-independent function of EZH2 plays a predominant role in supporting the growth and proliferation of SWI/SNF-mutant cells. Inhibiting the methyltransferase activity of EZH2 may therefore not be sufficient to fully block its oncogenic effects.


---

**Note:** Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.
CANCER DISCOVERY

Vitamin C Targets GAPDH to Kill KRAS- and BRAF-Mutant Cancer Cells


Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-RW2015-219

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerdiscovery.aacrjournals.org/content/6/1/13.1. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.